Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma

Anti-Cancer Drugs

Volumn 16, Issue 9, 2005, Pages 945-951

  Harris, Susan M ^a   Scott, John A ^a   Brown, Jeffrey L ^b   Charlton, Peter A ^a   Mistry, Prakash ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Anti cancer; Carboplatin; Combination therapy; Doxorubicin; Non small cell lung carcinoma; Xenografts; XR5944

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOXORUBICIN; MLN 944; PHENAZINE DERIVATIVE; UNCLASSIFIED DRUG; XR 5944;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; MOLECULAR STRUCTURE; PHENAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 26244460585     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000176499.17939.56     Document Type: Article

References (26)

1. Stewart AJ, Mistry P, Dangerfield W, Bootle D, Baker M, Kofler B, et al. Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs 2001; 12:359-367.
2. Cree IA, Nicolantonio F, Neale MH, Charlton PA. Ex vivo activity of two novel dual topoisomerase I and II inhibitors XR5944 and XR11576 against solid tumors. Clin Cancer Res 2001; 7 (Suppl):3746.
3. Gamage SA, Spicer JA, Finlay GJ, Stewart AJ, Charlton P, Baguley BC, Denny WA. Dicatonic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. J Med Chem 2001; 44: 1407-1415.
4. Sappal DS, McClendon AK, Fleming JA, Thoroddsen V, Connolly K, Reimer C, et al. Biological characterization of MLN944: a potent DNA binding agent. Mol Cancer Ther 2004; 3:47-58.
5. Fleming JA, Blackman RK, Thoroddsen V, Rudolph-Owen LA, Charlton P, Bulawa C. Using yeast to probe the mechanism of action of MLN944 (XR5944), a novel bis-phenazine with potent anti-tumor activity. Proc Am Ass Cancer Res 2003; 44:1316.
6. Sappal D, Mistry P, Rudolph-Owen LA. MLN944 (XR5944) regulates cell cycle progression by a novel mechanism compared to known topoisomerase inhibitors. Proc Am Ass Cancer Res 2003; 44:546.
7. cdc2/cyclin B. Cancer Res 1992; 52:1823-1829.
8. 2 cell cycle arrest after adriamycin-induced damage in mouse Swiss3T3 cells. FEBS Lett 1999; 461:299-305.
9. Ueno M, Nonaka S, Yamazaki R, Deguchi N, Murai M. SN-38 induces cell cycle arrest and apoptosis in human testicular cancer. Eur Urol 2002; 42:390-397.
10. Dancy J, Le Chevalier T. Non-small cell lung cancer: an overview of current management. Eur J Cancer 1997; 33:S2-S77.
11. Natale RB. Overview of current and future chemotherapeutic agents in non-small cell lung cancer. Semin Oncol 1997; 24:S72-9-S73-7.
12. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, et al. Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/ cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13:1539-1549.
13. Le Chevalier T, Pujol JL, Douillard JY, Alberola V, Monnier A, Riviere A, et al. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. Semin Oncol 1994; 21: 28-33.
14. Kusaba H, Tamura T, Shimoyama T, Hotta K, Inoue A, Nokihara H, et al. Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer. Jpn J Clin Oncol 2002; 32:43-47.
15. Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999; 80:981-990.
16. Harris SM, Mistry P, Freathy C, Brown JL, Charlton PA. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluroruracil and irinotecan in colon cancer cell lines. Br J Cancer 2005; 92:722-728.
17. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
18. Chou T, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Reg 1984; 22:27-55.
19. Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 2002; 87:825-833.
20. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001; 7:2168-2181.
21. O'Loughlin C, Heenan M, Coyle S, Clynes M. Altered cell cycle response of drug-resistant lung carcinoma cells to doxorubicin. Eur J Cancer 2000; 36:1149-1160.
22. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982; 9:140-147.
23. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KR. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev. 1985; (Suppl A):51-57.
24. Koeller JM, Trump DL, Tutsch KD, Earhart RH, Davis TE, Tormey DC. Phase I clinical trial and pharmacokinetics of carboplatin (NSC241240) by single monthly 30-minute infusion. Cancer 1986; 57:222-225.
25. Creasey WA, McIntosh LS, Brescia T, Odujinrin O, Aspnes GT, Murray E, et al. Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. Cancer Res 1976; 36:216-221.
26. Krivit W. Adriamycin cardiotoxicity amelioration by alpha-tocopherol. Am J Pediatr Hematol Oncol 1979; 1:151-153